Compare Trump Media and Technology Group Corp (DJT) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Trump Media and Technology Group Corp vs TG Therapeutics Inc — how do they compare? Trump Media and Technology Group Corp trades at $9.52 (market cap $2.50B), while TG Therapeutics Inc trades at $56.05 (market cap $8.41B). The key difference: TG Therapeutics Inc is far larger — about 3.4× Trump Media and Technology Group Corp's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Trump Media and Technology Group Corp nearer its low. Which is the better fit depends on your goals.
| DJT | TGTX | |
|---|---|---|
Market Cap | $2.50B | $8.41B |
Sector | Media | Health |
52-Week High | $19.86 | $59.06 |
52-Week Low | $7.06 | $26.39 |
Enterprise Value | $2.45B | $8.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.
The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Trump Media and Technology Group Corp
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
